Preliminary Anatomical and Neurodevelopmental Outcomes of Intravitreal Bevacizumab As Adjunctive Treatment for Retinopathy of Prematurity


Araz-Ersan B., Kir N., Tuncer S., Aydinoglu-Candan O., Yildiz-Inec D., Akdogan B., ...More

CURRENT EYE RESEARCH, vol.40, no.6, pp.585-591, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 6
  • Publication Date: 2015
  • Doi Number: 10.3109/02713683.2014.941070
  • Journal Name: CURRENT EYE RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Page Numbers: pp.585-591
  • Keywords: Antivascular endothelial growth factor, bevacizumab, retinopathy of prematurity, ENDOTHELIAL GROWTH-FACTOR, INJECTION, SAFETY, AVASTIN, BAYLEY, CHILD, ROP
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No

Abstract

Purpose: To evaluate the two-year follow-up of patients with type 1 retinopathy of prematurity (ROP) who received intravitreal bevacizumab (IVB) as adjunctive treatment.